Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the best, or even the only,option for the cure of leukemia, especially for patients with high risk factors.1 However, it is limited by the shortage of suitable donors, because only 25%-30% patients can find a human leukocyte antigen (HLA)-identical sibling donor.